Search

Your search keyword '"Del Barco, S"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Del Barco, S" Remove constraint Author: "Del Barco, S" Journal annals of oncology Remove constraint Journal: annals of oncology
24 results on '"Del Barco, S"'

Search Results

3. Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals

4. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial

5. Updated analysis of the national registry of nervous system tumours in Spain (RETSINE). RETSINE: National registry of nervous system tumours of the Spanish research group in neuro-oncology (GEINO) and Spanish infrequent and orphan tumours group (GETHI)

6. Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study

7. Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study

8. Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study)

12. MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study

13. Characteristics of gliobastomas (GBM) not resected (only biopsied) homogeneosuly treated with Stupp regimen. Results from the GLIOCAT study

14. Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study

15. Concomitant chemoradiation (Ch-RT) in elderly newly diagnosed glioblastoma (GB) patients. Updated clinical outcome and molecular characteristics from the GLIOCAT study

18. 148O - Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study

19. Geinofote: Safety and Activity Analysis of the Use of Fotemustine (Ft) in Different Schedules in Progressive Glioblastoma (Gb) in Spain

21. 347P - Long-term survivors (LTS) in glioblastoma (GBM) patients (pts) homogeneously treated with the Stupp regimen, clinical and molecular characteristics (MGMT and IDH1 status). Initial results from the GLIOCAT study

23. 338P - MGMT methylated (Met) patients (p) with glioblastoma (GBM) have a better prognosis with an earlier response (ER) than those who have a late response or pseudoprogression (LR/PsP). Results of the Gliocat study

24. 430P - Geinofote: Safety and Activity Analysis of the Use of Fotemustine (Ft) in Different Schedules in Progressive Glioblastoma (Gb) in Spain

Catalog

Books, media, physical & digital resources